Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | HRH2 | P25021 | 2/20 | 0.36 |
| ▸ | HRH1 | P35367 | 2/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30135752 | 0.91 | POLB (0.55) | SMN1; SMN2LMNAPOLBOPRD1OPRK1 | |
| SCHEMBL30732546 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAPOLBOPRD1OPRK1 | |
| SCHEMBL15569374 | 0.78 | POLB (0.50) | SMN1; SMN2LMNAPOLBOPRD1OPRK1 | |
| SCHEMBL15569373 | 0.78 | POLB (0.50) | SMN1; SMN2LMNAPOLBOPRD1OPRK1 | |
| SCHEMBL4368186 | 0.78 | SMN1; SMN2 (0.53) | SMN1; SMN2LMNAPOLBOPRD1OPRK1 | |
| SCHEMBL30075831 | 0.77 | SMN1; SMN2 (0.49) | SMN1; SMN2LMNAPOLBOPRD1OPRK1 | |
| SCHEMBL31386109 | 0.77 | POLB (0.52) | SMN1; SMN2LMNAPOLBOPRD1OPRK1 | |
| SCHEMBL1269471 | 0.77 | TSHR (0.49) | SMN1; SMN2LMNAPOLBATMALDH1A1 | |
| SCHEMBL12328494 | 0.76 | POLB (0.51) | SMN1; SMN2LMNAPOLBOPRD1OPRK1 | |
| SCHEMBL27842859 | 0.76 | POLB (0.58) | SMN1; SMN2LMNAPOLBOPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12435046-B2 | Alkynyl quinazoline compounds | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2025-10-07 | — | — | US | disclosed |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS, INC. | 2022-09-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12435046-B2 | Alkynyl quinazoline compounds | GLS, GLS2, MCL1 | SMN1; SMN2 206/4885LMNA 557/4885POLB 595/4885 |
| US-20220298120-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | GLS, GLS2, MCL1 | SMN1; SMN2 206/4885LMNA 557/4885POLB 595/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.